Neuronetics, Inc. (STIM)
NasdaqGM · USD · Healthcare · Medical Devices
$2.24 (+6.16%) as of
Key statistics
- Market cap
- 170.68M
- Forward P/E
- -6.59
- EPS (TTM)
- -0.4300
- Dividend yield
- 0.00%
- 52-week range
- 0.8000 – 3.4400
- Beta
- 1.20
- Revenue (TTM)
- 155.1M
- Profit margin
- -19.62%
- Analyst target
- $5.75
- Volume
- 1.10M
About Neuronetics, Inc.
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Malvern, PA, United States
- Employees
- 658
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.